131 results about "Prostaglandin" patented technology

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and / or prostaglandin levels include 15-PGDH inhibitors described herein.

The present invention relates to a method for in vitro sorting of target cells for cell therapy, belonging to the technical field of cell therapy. The present invention utilizes a washing solution containing EGTA, EDTA, α-casein, and prostaglandins to achieve a sorting method with high viable cell recovery efficiency, thereby enabling better cell therapy.

The invention belongs to the technical field of biology, and particularly relates to a composition for tumor targeted therapy, hydrogel and a preparation method and application thereof. The tumor targeted therapy composition provided by the invention comprises the aging tumor cells and the celecoxib, the immune activation function of the aging tumor cells is that STCs can effectively activate the maturation of dendritic cells and the immune function of T cells and NK cells, SASP of the STCs is regulated through the celecoxib, especially generation of prostaglandin E2 is inhibited, and the tumor targeted therapy effect is improved. And the combined use further enhances the anti-tumor immune effect.

The invention relates to the technical field of equipment control, and discloses a control method of a wave conduction health care instrument capable of outputting different waveforms based on symptoms, and the method comprises the steps: transmitting a 1-10MHz multi-frequency detection wave to a target treatment area, calculating tissue impedance distribution through a reflected wave, and obtaining a focus boundary coordinate based on an impedance difference threshold; on the basis of the impedance-frequency response curve, an inverse phase compensation waveform is generated through a time reversal algorithm, the inverse phase compensation waveform comprises a phase delay component in negative correlation with the impedance curve, and tissue scattering distortion is counteracted; synchronously starting the electrical stimulation module and the ultrasonic module; the focus coordinates are repeatedly updated every 30 seconds, and the electrical stimulation focusing position is adjusted; the concentration of lactic acid and the concentration of prostaglandin E2 in tissue fluid are detected in real time through a microfluidic sensor, and correction is triggered when any concentration exceeds the limit, specifically, lactic acid ultralimit switching electrical stimulation is 50-100 Hz damped oscillatory waves (larger than or equal to 5 minutes), prostaglandin E2 ultralimit switching ultrasound is in a pulse mode, and the electrical stimulation amplitude is increased. The treatment effect of the waveform treatment equipment can be improved.

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

The invention discloses an anti-drunkenness composition and application thereof. The invention provides an application of a composition in preparation of an anti-drunkenness product, the composition contains edible plasma powder, xylitol, fructo-oligosaccharide, microcrystalline cellulose, mogroside and magnesium stearate, and the edible plasma powder contains immune globulin IgG. The TZK provided by the invention has obvious regulation and improvement effects on sleep behaviors, serum indexes and gastrointestinal injury after acute drinking. The oxidative stress state after long-term large-dose chronic drinking is effectively adjusted, so that the oxidative stress injury index malondialdehyde (MDA) gradually returns to the normal level; according to the present invention, the activity of the liver injury markers such as alanine transaminase (ALT) and aspartate transaminase (AST) is reduced, the liver protection effect is provided, and the gastric mucosa structure repair is promoted by increasing the gastric mucosa prostaglandin content and reducing the local MDA level;

This invention provides a method for the simultaneous and rapid detection of four oxidative stress-related biomarkers and its application. The detection method includes: (S1) pretreatment of samples using a protein precipitation extract to simultaneously extract four target compounds: 8-hydroxydeoxyguanosine, 8-isoprostaglandin F2β, 8-isoprostaglandin F2α, and acetyllysine, and preparing a test solution; the protein precipitation extract is a methanol-acetonitrile-perchloric acid mixed solution containing formic acid, wherein the volume ratio of methanol, acetonitrile, and perchloric acid is (8-10):(8-10):(0.5-1), and the volume concentration of formic acid is 0.1-0.5%; (S2) detection of the test solution and standard solution using liquid chromatography-tandem mass spectrometry, and matrix calibration using an internal standard method; plotting a standard curve with the peak area ratio of the target compound to the internal standard as the ordinate and the concentration as the abscissa; and calculating the concentration of the target compound in the test solution based on the standard curve.

Provided are intermittent administration methods for reducing toxicity in the treatment of conditions associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression levels in a subject with a 15-PGDH inhibitor. Further, provided herein are methods of treating a condition associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression level in a subject by administering a 15-PGDH inhibitor while maintaining the therapeutic effect of the 15-PGDH inhibitor when the plasma concentration of the 15-PGDH inhibitor in the subject drops below the EC50 of the 15-PGDH inhibitor.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group; and at least one co-monomer of Formula III J-(Y1-A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising these compounds. The compounds provided herein can be used as prostaglandin E2 (PGE2) EP4 receptor antagonists, which makes them very useful for therapy, particularly for the treatment or prevention of cancer, neovascular eye disease, inflammatory pain or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or endometriosis. #imgabs0#

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

The present disclosure relates to genetically modified host cells producing prostaglandins, to genetic constructs for expression of such mutants; to cultures of the genetically modified host cells and its use to produce the said products; to fermentation liquids comprising the said products resulting from such production; to compositions comprising the fermentation liquid; to pharmaceutical preparations made from such compositions and to the uses of such compositions and preparations.

This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

This invention relates to a method for preparing black ginseng concentrate and the black ginseng concentrate prepared by the above method. The method for preparing black ginseng concentrate is characterized by comprising the following steps: placing red ginseng in a continuous steam-drying machine to prepare black ginseng by steaming, cooling and drying; adding alcohol to the black ginseng powder prepared above and extracting and filtering to prepare black ginseng extract; and concentrating and heat-treating the prepared black ginseng extract using a plate evaporator.

Methods for the synthesis of a tricyclic-prostaglandin D2 metabolite methyl ester or a pharmaceutically acceptable salt thereof.

Sulfonyl-azole compounds (e.g., sulfonyl-imidazole compounds) and their use as covalent ligands for reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, e.g., to selectively form modified proteins and / or to alter the biological activity of the proteins are described. Sulfonyl-imidazole compounds for inhibiting particular proteins, such as prostaglandin reductase 2 (PTGR2) and glutathione S-transferase (GST) enzymes, are also described.

An injectable sustained release composition comprising a prostaglandin, which is formulated to release the prostaglandin in a sustained manner, and a method of inducing luteolysis of a functional luteum in an animal by sustained administration of a prostaglandin, such as PGF2 [alpha], preferably cloprostenol.

Respiratory muscle contraction inactivity during mechanical ventilation (MV) results in diaphragm weakness, which is called ventilator induced diaphragm dysfunction (VIDD). In different hypotheses to interpret the VIDD, one of the hypotheses involves the remodeling of the myoplasmic reticulum (SR) calcium release channel / Ryanodine receptor (RyR1) in the diaphragm as a proximal mechanism of the VIDD. The inventor has developed a novel derivative which can efficiently prevent VIDD in VIDD mouse and pig models. The effect is related to the homogenization of RyR function. Thus, the present invention relates to novel compounds and their use in the treatment of diseases associated with Ryanodine receptor (RyR) dysfunction.

The application belongs to the technical field of microorganisms, and provides a Streptococcus salivarius subsp. thermophilus HX-ST36, which has a preservation number of CGMCC NO. 32955. The Streptococcus salivarius subsp. thermophilus provided by the application can ferment Astragalus membranaceus Bunge-Angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrhea model mouse, the fermentation product thereof can significantly inhibit the writhing response, and can realize the effects of relieving dysmenorrhea and tonifying blood by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the hemoglobin (HGB) content. The effect of the fermentation product in removing dampness is verified by improving the dampness signs of a crowd. The application further provides a probiotic preparation and a preparation method of a probiotic fermentation product. The preparation method of the probiotic preparation and the probiotic fermentation product is simple and can be produced on a large scale.

The invention relates to the technical field of metabonomics analysis, in particular to application of a metabolic marker in preparation of a head and neck squamous cell carcinoma diagnostic product, a kit, a screening method of the metabolic marker of the head and neck squamous cell carcinoma, a diagnostic model and a construction method and application of the diagnostic model. The metabolic marker comprises at least one of lactic acid, sphingosine, cadaverine, uridine diphosphate, allantoic acid, hydroxyproline, sphingosine-1-phosphoric acid, indole-3-acetaldehyde, pantothenic acid, fumaric acid, malic acid, prostaglandin or ornithine in red blood cells and / or plasma. The screened red blood cells and plasma metabolism markers can be used for predicting or diagnosing the head and neck squamous cell carcinoma respectively or independently, particularly, the red blood cell metabolism markers can provide more stable tumor microenvironment information, and the metabolism stability is high and is not easily influenced by diet and circadian rhythm.

The invention discloses an efficient oxytocic for hippocampus in the late pregnancy period and an oxytocic method of the efficient oxytocic. Research verifies that the odinagogue taking prostaglandin E2 as a main active component can rapidly induce the hippocampus to give birth in the late pregnancy (take effect within 60 minutes after odinagogue), and the odinagogue time is remarkably shortened. The juvenile fish produced by the method has independent viability, has no significant adverse effect on the sea horse with incomplete embryonic development, can effectively improve the mature fry acquisition rate when the embryonic development condition is unknown, reduces the fry loss in the culture process, and is beneficial to sea horse resource protection and industrial layout optimization.

The invention discloses a sleep-aiding pomegranate wine. The pomegranate juice wine is prepared from the following components through three times of gradient fermentation and blending: pomegranate juice primary fermented wine with the volume ratio of 60 + / -2%, the alcoholic strength of 8-9% vol and the fermentation temperature of 1-3 DEG C; the pomegranate rind processing wine has a volume ratio of 10 + / -1%, the pomegranate rind is processed by a traditional Chinese medicine processing technology, and then low-temperature extraction is carried out at an extraction temperature of less than or equal to 50 DEG C; flavonoid compounds (such as quercetin and kaempferol) in pomegranate seeds can inhibit the activity of epoxidase-2 (COX-2) and reduce the release of inflammatory factors such as prostaglandin E2 (PGE2) (experimental data: the inhibition rate is greater than or equal to 65%); vitamin C and polyphenol cooperate to promote joint synovial cells to secrete hyaluronic acid, the viscoelasticity of the joint lubricating fluid is improved (the viscosity is increased by 30%), and the pain of osteoarthritis is relieved.

The present invention relates to the field of pharmaceutical applications, and in particular to a marker for viral pneumonia and its application, wherein the marker for viral pneumonia is prostaglandin E2 and / or prostaglandin M. The present invention uses prostaglandin E2 and / or prostaglandin M as markers for viral pneumonia, and the use of cyclooxygenase II inhibitors can effectively and quickly reduce prostaglandins, reverse the progression of common and severe cases, block the occurrence of critical illness, promote viral conversion to negative, pneumonia absorption and health recovery. The drug will expand its clinical use scope upon further confirmation of its efficacy, incorporate the treatment method into clinical diagnosis and treatment plans, and provide new strategies and diagnosis and treatment methods for the comprehensive treatment of new coronary pneumonia.

Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin level.